Skip to main content

ORTHOFIX International N V Value Stock - Dividend - Research Selection

Orthofix international n v

ISIN: US68752M1080 , WKN: A2NB0X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. Orthofix International N.V. was founded in 1987 and is headquartered in Lewisville, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


A Glimpse Into The Expert Outlook On Orthofix Medical Through 5 Analysts

2026-03-09

Stifel Maintains Buy on Orthofix Medical, Lowers Price Target to $18

2026-03-09
Stifel analyst Thomas Stephan maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $22 to $18.

Canaccord Genuity Maintains Buy on Orthofix Medical, Lowers Price Target to $20

2026-02-26
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $24 to $20.

Orthofix Medical Inc (NASDAQ:OFIX) Posts Strong Q4 Profit Beat Despite Revenue Miss, Provides 2026 Outlook

2026-02-24
Orthofix Q4 earnings beat profit forecasts with strong margin growth and free cash flow, despite a slight revenue miss. The company provides 2026 guidance focused on expansion.

Orthofix Medical Inc. (OFIX) Q4 2025 Earnings Call Transcript

2026-02-24

Orthofix Medical Inc. 2025 Q4 - Results - Earnings Call Presentation

2026-02-24

Orthofix Medical Earnings Review: Q4 Summary

2026-02-24

Orthofix Medical Sees FY2026 Sales $850.000M-$860.000M vs $862.758M Est

2026-02-24
Orthofix Medical (NASDAQ:OFIX) sees FY2026 sales of $850.000 million-$860.000 million vs $862.758 million analyst estimate.

Orthofix Medical Q4 Adj. EPS $0.24 Beats $0.12 Estimate, Sales $219.911M Beat $218.861M Estimate.

2026-02-24
Orthofix Medical (NASDAQ:OFIX) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.12 by 100 percent. This is a 1100 percent increase over earnings of $0.02 per share from the

Earnings Scheduled For February 24, 2026

2026-02-24